Autoantibodies against oxidized low-density lipoprotein in antiphospholipid syndrome.
The prevalence and clinical significance of anti-oxidized low-density lipoprotein antibodies (anti-ox-LDL) were evaluated in patients with the antiphospholipid syndrome (APS).
Anti-ox-LDL were measured in the sera of 107 patients with APS (64 primary APS. 43 secondary to systemic lupus erythematosus) by enzyme-linked immunosorbent assay (ELISA) utilizing malondialdehyde (MDA) - modified LDL as antigen.
In the same patients, anticardiolipin antibodies (aCL) and anti-/12-glycoprotein I antibodies (anti-bêta2GPI), were also measured.
A positive titre of anti-ox-LDL was detected in 22% of patients, but only in 6% of control subjects (X2=12.
Levels of anti-ox-LDL were higher in patients with arterial thrombosis (n=58) than in those without (n=49) (P=0.0001).
Anti-ox-LDL levels correlated weakly with those of aCL (r=0.196, P=0.043). but not with those of anti-bêta2GPI (r=0.076).
Our findings suggest that elevated levels of anti-ox-LDL may represent another potential marker of APS, particularly of patients prone to arterial thrombosis.
Mots-clés Pascal : Antiphospholipide syndrome, Anticorps, Autoanticorps, Epidémiologie, Prévalence, Lipoprotéine LDL, Etat oxydé, Symptomatologie, Pathogénie, Thrombose, Artère, Homme, Thrombocyte, Appareil circulatoire pathologie, Vaisseau sanguin pathologie, Hémopathie, Immunopathologie, Maladie autoimmune, Artère pathologie
Mots-clés Pascal anglais : Antiphospholipid antibody syndrome, Antibody, Autoantibody, Epidemiology, Prevalence, Lipoprotein LDL, Oxidized state, Symptomatology, Pathogenesis, Thrombosis, Artery, Human, Platelet, Cardiovascular disease, Vascular disease, Hemopathy, Immunopathology, Autoimmune disease, Arterial disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0500665
Code Inist : 002B07. Création : 13/02/1998.